Gilead Sciences, Inc (GIS) Stock Price & News

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia

About Gilead Sciences, Inc

CEODaniel O'Day

Employees17 k

Founded22 Jun. 1987

HeadquartersFoster City, Kalifornië, Verenigde State van Amerika

Sector-

Websitegilead.com

All values in USD	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	7,77 mjd	7,92 mjd	6,96 mjd	7,80 mjd
Cost of goods sold	1,57 mjd	1,62 mjd	1,44 mjd	1,58 mjd
Cost of revenue	1,57 mjd	1,62 mjd	1,44 mjd	1,58 mjd
Research and development expenses	1,33 mjd	1,57 mjd	1,36 mjd	1,69 mjd
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1,35 mjd	1,78 mjd	1,43 mjd	1,91 mjd
Operating expense	2,69 mjd	3,34 mjd	2,78 mjd	3,60 mjd
Total operating expenses	4,26 mjd	4,96 mjd	4,23 mjd	5,18 mjd
Operating income	3,51 mjd	2,96 mjd	2,73 mjd	2,63 mjd
Other non operating income	-23,00 m	51,00 m	-8,00 m	-
EBT including unusual items	3,64 mjd	2,08 mjd	2,58 mjd	-10,25 mjd
EBT excluding unusual items	3,34 mjd	2,80 mjd	2,59 mjd	2,42 mjd
Income tax expense	589,00 m	-105,00 m	559,00 m	242,00 m
Effective tax rate	16,18%	-5,05%	21,67%	-2,36%
Other operating expenses	-	-	-	-
Net income	3,05 mjd	2,18 mjd	2,02 mjd	-10,50 mjd
Net profit margin	39,28%	27,55%	29,04%	-134,51%
Earnings per share	2,47	1,86	2,03	-6,75
Interest and investment income	88,00 m	95,00 m	95,00 m	45,00 m
Interest expense	-256,00 m	-255,00 m	-240,00 m	-247,00 m
Net interest expenses	-168,00 m	-160,00 m	-145,00 m	-202,00 m
Depreciation and amortization charges	-	-	-	-
EBITDA	4,20 mjd	3,65 mjd	3,42 mjd	3,33 mjd
Gain or loss from assets sale	-	-	-	-

Ask anything